Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Square-wave insulin aspart bolus dosing for breakfast in type 1 diabetes
ACTRN12612000609853Phase 4Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in diabetes mellitus type 1 (T1D) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Postprandial blood glucose excursion. Planned start Jul 2012; status: not yet recruiting.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12612000609853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000609853.